ProKidney Corp. (NASDAQ:PROK - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 1,138,769 shares were traded during trading, an increase of 108% from the previous session's volume of 547,226 shares.The stock last traded at $2.29 and had previously closed at $1.75.
Analyst Ratings Changes
A number of research analysts have issued reports on PROK shares. Morgan Stanley started coverage on shares of ProKidney in a report on Thursday, March 7th. They issued an "equal weight" rating and a $3.00 target price for the company. Bank of America cut shares of ProKidney from a "buy" rating to a "neutral" rating in a report on Tuesday, January 2nd.
Read Our Latest Stock Analysis on ProKidney
ProKidney Price Performance
The stock's 50-day moving average is $1.50 and its 200-day moving average is $1.81. The stock has a market cap of $479.32 million, a price-to-earnings ratio of -3.67 and a beta of 1.08.
ProKidney (NASDAQ:PROK - Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. Analysts predict that ProKidney Corp. will post -0.65 EPS for the current fiscal year.
Hedge Funds Weigh In On ProKidney
Hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC acquired a new position in shares of ProKidney in the 2nd quarter valued at $31,000. Tower Research Capital LLC TRC lifted its holdings in shares of ProKidney by 98.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company's stock valued at $50,000 after acquiring an additional 2,211 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of ProKidney during the 2nd quarter valued at $57,000. UBS Group AG lifted its holdings in shares of ProKidney by 97.5% during the 1st quarter. UBS Group AG now owns 5,209 shares of the company's stock valued at $59,000 after acquiring an additional 2,571 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of ProKidney by 530.3% during the 2nd quarter. Royal Bank of Canada now owns 6,965 shares of the company's stock valued at $78,000 after acquiring an additional 5,860 shares in the last quarter. Institutional investors and hedge funds own 51.59% of the company's stock.
ProKidney Company Profile
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
See Also
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
